Carcinoma Larynx; Evidence based management
Staging - Surgery - Adjuvant therapy - Organ Preservation - Altered fractionation, chemotherapy - Radiotherapy (RT) techniques, Role of IMRT
Carcinoma Larynx; Evidence based management
Staging - Surgery - Adjuvant therapy - Organ Preservation - Altered fractionation, chemotherapy - Radiotherapy (RT) techniques, Role of IMRT
This is a Central presentation, presented at National Institute of Cancer Research & Hospital(NICRH), Mohakhali, Dhaka, Bangladesh on Metastatic neck node of unknown primary.
Management of supraglottic and glottic larynx cancer has been revised lately. This presentation gives an overview of guidelines for management of laryngeal cancer. includes latest NCCN guidelines.
Nasopharyngeal carcinoma is a non lymphomatous squamous-cell carcinoma that occurs in the epithelial lining of the nasopharynx.
It frequently arises from the pharyngeal recess (fossa of Rosenmuller) posteromedial to the medial crura of the eustachian tube opening in the nasopharynx
This is a Central presentation, presented at National Institute of Cancer Research & Hospital(NICRH), Mohakhali, Dhaka, Bangladesh on Metastatic neck node of unknown primary.
Management of supraglottic and glottic larynx cancer has been revised lately. This presentation gives an overview of guidelines for management of laryngeal cancer. includes latest NCCN guidelines.
Nasopharyngeal carcinoma is a non lymphomatous squamous-cell carcinoma that occurs in the epithelial lining of the nasopharynx.
It frequently arises from the pharyngeal recess (fossa of Rosenmuller) posteromedial to the medial crura of the eustachian tube opening in the nasopharynx
Slides prepared by highly experienced ENT teacher, Dr. Krishna Koirala from Nepal , for teaching undergraduate and postgraduate MBBS students in the field of otorhinolaryngology. A clear and concise explanation of the basic concepts in the subject matter concerned. He is the Head of department with a sound knowledge in the field of ENT to teach both undergraduate and postgraduate ENT students
Slides prepared and compiled by highly experienced ENT teacher, Dr. Krishna Koirala from Nepal , for teaching undergraduate and postgraduate ENT students in the field of otorhinolaryngology.
A clear and concise explanation of the basic concepts in the subject matter concerned.
He is the Head of department with a sound knowledge in the field of ENT to teach both undergraduate and postgraduate ENT students
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
6. Lymphatic Drainage
• Rich lymphatic plexus – roof, posterior,
lateral walls
• Three lymph node collecting stations
1. RP node of Rouviere
2. Jugular chain – upper lateral JD nodes
3. Upper deep cervical node at the confluence
of Spinal accessory
• Lymphatic capillary plexus – lymphiod
aggregates in the pharyngeal tonsil &
tubal tonsil
7. • RP nodes – lateral parapharyngeal space
• RP nodes – proximity to 9,10,11,12
• Classic NP node – 3-4 high lateral jugular
nodes that lie deep into SCM and lateral to
IJV
8. • Lymph collectors
• Lateral side of the pharyngeal wall
• The lateral lymph collector empties into
multiple first-tier nodes (lateral pharyngeal
node, the jugulodigastric/subdigastric
nodes, 3,4,5 RP group
• The posterior lymph collector empties into
the first node (node of Rouviere) of RP
13. Epidemiology
• Highest in china 3/100,000
• Bimodal age distribution 15-25 yrs & 50-59yrs
• Causation is multifactorial involving
environmental, genetic and familial and viral
factors
• Early lymphatic spread and notorious
predilection for distant metastases
• Anatomical proximity to critical structures
makes surgical extirpation difficult without
morbidity.
• RADIOSENSITIVE
14. Etiology
• Genetic
• Environmental
Salted fish in southern china
Dimethyl nitrosamine
Alcohol, cigarette, dust etc
• Viral – EBV
NPC non keratinising type
Tumorigenic potential – LMP 1, 2A, 2B
Nuclear antigens – EBNA1 & 2
15. Natural history
• Local extension
Anterior – nasal fossa → lateral walls of nasal
fossa → destruction of pterygoid plates
• Ethmoid, maxillary sinus less common
• Advanced disease orbital invasion
• Superior & Posterior
Base of skull, sphenoid sinus,clivus
Cavernous sinus,
• Inferiorly – tonsillar pillar, tonsillar
fossa, oropharyngeal wall
16. Border Spread Significance
Lateral Parapharyngeal
Space
Fossa of Rosenmuller is the most common
site for NPC. Retroparotidian syndrome =
involvement of CN IX–XII and cervical
sympathetics
Masticator space Trismus
anterior Pterygopalatie
fossa (PPF) via
sphenopalatine
foramen from nasal
cavity
Tumors can extend proximally along V2 from
PPF to cavernous sinus
Posterior Retropharyngeal
(RP) nodes and
prevertebral space
>75% patients - cN+, 90% - subclinical nodes,
40–50% b/l nodes. Level 2 & lateral RP nodes
are the first echelon
Superior Skull base Foramen ovale (CN V3) and foramen lacerum
commonly involved. True intracranial
extension is uncommon (<10%).
Petrosphenoidal syndrome = extension
through foramen lacerum to cavernous sinus
Inferior Hard palate
(oropharynx)
Infrequent
27. Work up & Evaluation
• Complete head & neck physical exam
Node – size, mobility, extent of enlarged node
Vision, hearing
Exclusion of gross signs of DM
• Nasopharyngoscopy + Biopsy of Primary / FNAC
• Labs – CBC, LFT , EBV titers (IgA anti VCA, IgG
anti EA)
• Chest X ray
• CT brain + PNS + Neck
• MRI with contrast include skull base,
nasopharynx, and neck to clavicles
28. • MRI better sensitivity than CT
• Detection rates of MRI and CT Scan compared
• IC Extension 57 % vs. 36 %
• Skull base involvement 60 % vs. 40 %
• Retropharyngeal node 58 % vs. 21 %
• Prevertebral muscle infiltration 51 % vs. 22 %
• MRI detected bone erosion in all cases, as seen on
CT
• Upstage of T stage in 22%, downstage in 4 %
29. • Metastatic work up
PET-CT (especially for non-keratinizing
histology, endemic phenotype, N2 or N3, and
stage III –IV)
CT chest & abdomen
Bone scan
31. Differentials
• If small nasopharyngeal mass and confined to
the mucosa:
Prominent, but normal adenoidal tissue
Nasopharyngeal lymphoma
Early primary nasopharyngeal malignancy
32. • If larger nasopharyngeal mass +/-involvement of
the skull base:
Primary nasopharyngeal malignancy
Adenoid cystic carcinoma
Papillary adenocarcinoma
Melanoma
Plasmacytoma
Lymphoma
Chordoma/Chondrosarcoma
Meningioma
Rhabdomyosarcoma/other sarcoma
33. Histopathology
• Poorly differentiated carcinoma
• Pleomorphic epithelioid cells in a background
of lymphocytes
• Presence of keratin – adverse prognostic factor
35. AJCC 8th Edition
T Criteria
Tx Primary Tumor cannot be assessed
T0 Tumor identified, EBV + CERVICAL NODES
T1 Tumor Confined to NP or extension to oropharynx/nasal cavity
WITHOUT PARAPHARYNGEAL INVOLVEMENT
T2 Tumour with extension to PARAPHARYNGEAL SPACE and/or
adjacent soft tissue involvement (medial pterygoid, lateral
pterygoid, prevertebral muscles)
T3 Tumour invades BONY STRUCTURES of skull base cervical
vertebra, pterygoid structures, and/or PARANASAL SINUSES
T4 Tumour with INTRACRANIAL EXTENSION, involvement of
cranial nerves, hypopharynx, orbit, PAROTID GLAND and/or
extensive soft tissue infiltration beyond the lateral surface of the
lateral pterygoid muscle
36. N Criteria
Nx Regional LN cannot be assessed
N0 No regional LN
N1 UNILATERAL metastasis, in cervical lymph node(s),
and/or unilateral or bilateral metastasis in
RETROPHARYNGEAL LN, 6 cm or less ,above the
caudal border of cricoid cartilage
N2 BILATERAL metastasis in cervical lymph node(s), 6
cm or less ABOVE the caudal border of cricoid
cartilage
N3 Metastasis in cervical lymph node(s) GREATER
THAN 6 CM in dimension and/or extension BELOW
the caudal border of cricoid cartilage
37. Staging
T1 T2 T3 T4
N0 I II III IVA
N1 II II III IVA
N2 III III III IVA
N3 IVA IVA IVA IVA
M1 IVB IVB IVB IVB
38. Prognostic factors
Younger age & female sex – better prognosis
Histology – non keratinizing & undifferentiated –
more radiosensitive – better prognosis
Advanced T stage – worse LC
Advanced N stage – increased risk of DM & worse
survival
EBV DNA load – higher recurrence
EGFR, VEGF over expression – poor
39. Treatment strategy
• Surgery difficult ; only role in:
Biopsy for pathologic diagnosis
Salvage for persistent / recurrent disease
• RT ALONE / IN COMBINATION WITH CT
42. Chemo radiotherapy
ARM 3Yr SURVIVAL 5Yr SURVIVAL DM RATE
RT 56.38% 41.09% 38.71%
CRT 68.74% 51.91% 26.19%
The result demonstrated that
CRT increased overall survival by 12% at 3 years, and 11% at 5
years.
After CRT, the rate of distant metastasis was reduced by 12%.
Meta-analysis included 18 trials enrolling a total of 1993 patients from China.
Yank AK,Liu TR, Guo x, QI gl, Chen FJ.
43. Dose
Dose T stage Local Tumor Control
Rate(%)
>70Gy T1 T2 100
66-70 Gy T1 T2 80
>70GY T3 T4 <55
60 Gy T1 T2 76
TOTAL DOSE IMPORTANT
DOSE FRACTION NOT
70Gy/35#/7weeks to GTV
50-60 Gy for potential risk sites
FRACTIONAL DOSE OF > 2Gy SHOULD BE AVOIDED
44. Pediatric
• Per COG ARAR 0331 protocol
• Stage I: RT alone (61.2/1.8 Gy for Stage I;
66.6/1.8 Gy for StageII)
• Stage ≥ II: Cisplatin/5-FU × 3c → RT (CR/PR to
chemo 61.2/1.8 Gy, SD to chemo 70.2/1.8 Gy)
and concurrent cisplatin
• 36–46/2–3 Gy to unresectable metastases
46. Conventional set up
• Direct marking open field
• Simulator
• 3 fields; 2 lateral opposed for primary and
upper neck, matched to 1 anterior field for
lower neck.
47. Portals
B/L parallel opposed portals for primary & upper neck
• Superior : 2 to 2.5 cm above the zygomatic arch and
splits the pituitary fossa. In case of base of skull
involvement or intracranial extension it is taken 4.0
to 5.0 cm above the zygomatic arch or 1 cm above
the pituitary fossa.
• Inferior : at the thyroid notch
• Anterior : encompasses posterior ½ of nasal cavity
or moved forward to cover the extensions if any.
• Posterior : kept open to cover the posterior triangle
48. • Single anterior portal for lower neck
Superior : matched to the inferior border of the lateral
fields.
Inferior : extend below to cover the lower edge of
clavicles.
Lateral : cover medial 2/3rd of the clavicle.
49.
50.
51. Dose prescription
• Phase I : 40 to 44 GY in 20 to 22 fractions @ 2GY/#.
• Phase II : fields are shrinked to avoid the spinal cord.
• Primary tumor is boosted to an additional 20 to 25
GY.
• T1 & T2 tumor : 60 to 65 GY
• T3 & T4 tumor : 70 to 75 GY.
• Dose to neck nodes : 45 to 50 GY to N0 neck.
53. Limitations of Conventional RT
• rectangular-shaped - suboptimal target
coverage and inclusion of large volumes of
normal tissues
• high rate of xerostomia
• Carotid stenosis
• Cranial nerve palsy
• Dose escalation difficult
54. Conformal
• Immobilisation device orfit making
• Neck extended, shoulder down
• Fiducial markers
• Laser matching
• Topogram
• IV contrast
• Upto the level of carina
56. Rationale for IMRT
• Anatomically complex H&N region
• Treat target volumes adjacent to critical or
sensitive normal tissues
• Lack of organ motion in the H&N region
• Allows for dose escalation , allows for
concomitant boost.
58. Inverse Planning
• Desired dosimetric & clinical objectives are
stated mathematically
• Appropriate specifications for normal tissue
dose constraints
• Overstringent dose constraints to normal
tisues – ensure adequate dose cover to target
59. Forward Planning
• From field definition to dose distribution
• T/t parameters
• Dose calculation
• Dose distribution
• Dose delivery with uniform radiation
intensity
60. Inverse Planning
• From dose distribution to field definition
• Dose delivery with nonuniform radiation
Intensity
• leaf sequence generation
• optimization
• Treatment goals ( objective function )
63. OAR
• Critical normal structures
• Could suffer significant morbidities
• Might influence treatment planning & dose
prescription
• All non target tissues
• Depend on the location of ctv
64. Rhyme respecting cord & brainstem
• Brainstem – lower part of lateral ventricle
to odontiod apical
• Cord starts from odontoid apical upto 5cm
below PTV
• Check for missing slice – DON’T
INTERPOLATE
• Serial organs – maximum dose minimum
• Brain window
• PRV extra degree of freedom
65. • Optic nerve – delineating orbital part only
NOT IDEAL
• Draw till chiasm through optic canal
66. PTV
• Geometric concept for treatment planning
• Tool to shape absorbed dose distributions
• Ensure the delivery of dose to all parts of
ctv
• Despite organ motion & set up variations
68. LN Metastasis
• Ellipsoid
• Size ≥ 10mm (5mm RP)
• Central necrosis
• Extra capsular spread
• Clustered nodes 3 or more
69. CTV70
• GTV 70 + 5 mm
• Around the brainstem and spinal cord, 1-mm margin
• entire nasopharynx, sphenoid sinus, cavernous
sinus, base of skull, posterior ½ of nasal cavity,
posterior 1/3 of maxillary sinuses, post. Ethmoid
sinus, pterygoid fossa, lateral & posterior
pharyngeal wall, retropharyngeal nodes, & b/L
cervical nodes including level V & SCF.
70. SCOPE
• S – Sinus (Sphenoid, Max post 1/3), skull
base, soft palate
• C- Clivus, cavity nasal post 1/3, cavernous
sinus, cave meckels
• O – ovale foramen
• P – Pterygopalatine fossa, pterygoid fossa,
parapharyngeal space, proper nasopharynx,
• E- ethmoid posterior
71. PTV70
• CTV 70 + 3–5 mm
• Around the brainstem
and spinal cord 1-mm
72. PTV2 (59.4 Gy)
High risk subclinical disease:
Sphenoid sinus
Cavernous sinus
Skull base
Clivus
Posterior 1/3 of maxillary
sinus
Posterior 1/3 of nasal cavity
Pterygopalatine fossae
Parapharyngeal space
Retropharyngeal space
Soft palate
73. High risk nodal levels
• Include all bilaterally
• Upper deep jugular
• Level I submandibular
• Level II JD
• Level III mid jugular
• Level IV Low jugular & supraclavicular
• Level V Posterior cervical
• Retropharyngeal
77. Two different approaches
• Extended whole field EWF
Total target volume in the IMRT plan
• Split field SF
Target volume superior to vocal cord – IMRT
Lower neck – conventional anterior neck field
Dose to vocal cords minimum
80. • Other normal structures (lower priority):
• Parotids
• Dmean < 26 (atleast one gland)
• at least 20 cc of the combined volume of both parotid
glands to receive < 20 Gy,
• at least 50% of one gland to receive < 30 Gy
• TongueMax < 55 Gy
• Inner/middle ears Mean < 50 Gy
• (especially with concurrent Cisplatin)
• EyesMean < 35 Gy
• GlotticlarynxMean < 45 Gy
• Lens < 6
81. Delineating Parotid as OAR
• Identify the gland
• Mid aspect of the gland
• Then proceed cranially and caudally
• Boundaries
Cranial – EAC & Mastoid
Caudal – submandbular space
Anterior – masseteric muscle
Posterior - SCM
82. Simultaneous integrated boost SIB
• Simultaneously treat two or more volumes
• Different fraction sizes
• Use of same plan – less error
• Dose painting
89. Trial No Description DFS
International
NPC study
339 RT vs NACT+RT 54 vs 40
Me et al 456 RT vs NACT+RT
Cis+bleo+5FU
63 vs56
AOCOA 334 RT vs NACT +RT
Cis
48 vs 42
91. CDDP
• Pencillin of cancer
• Peyrone’s chloride
• Use with caution in altered RFT
• Hydrated before, after and post chemo
• Higher the dose more aggressive hydration (2L)
• Furosemide diuresis every 2L
• anti emetis (ondan, dexona, aprepitant)
• Nephrotoxic, ototoxic, neurotoxic
• Azoopermia, alopecia
92. CRT – key trials
Trial No Method DFS LRC Toxicity
NPC
9901
348 Conc
Cis+RT
No Adj CT
72 vs 62 92 vs 82 > CRT
arm
SQNP01 221 Al Sarraf
regimen
72 vs 53 > CRT
Taiwan 284 Cis/5Fu+RT
vs RT
72 vs 53 96.8 vs
92.1
93. Al Sarraf Trial
• 193 patients
Trial 5 yr
PFS
5 yr
OS
RT 29 37
Chemo RT + Adj RT 58 67
Adjuvant CT
Cisplatin / 5FU
Concurrent CRT (Cisplatin)
94. MAC-NPC meta-analysis (Blanchard,
Lancet Oncol 2015)
• 19 trials with 4806 pts.
• 5-yr OS benefit for concurrent and adjuvant
chemo (12.4%) or concurrent chemo alone
(9.4%)
96. Dose escalation
• Improvement in local tumor control rates
• External Beam RT
• Brachytherapy boost
• Stereotactic RT boost
97. Brachytherapy
• Suitable Candidate
Tumors restricted to Nasopharynx as BOOST
Thickness of CTV <10 mm - well circumscribed,
superficial local recurrences.
• Local control upto 90 – 95 % for T1-T2 tumours with
acceptable late toxicities
• Dose delivered through brachytherapy is adequate
only for superficial non-bulky tumours
• Outcome depends on accurate placement of the
catheters, which largely depends on patient anatomy
and clinician’s skill
98. • Boost minimal, local,residual local disease
• Salvage therapy well circumscribed
superficial local recurrences
100. RN Apllicator
• Made of soft silicone
• Endocavitary
• Well tolerated by patient
• The two silicone tubes, can accommodate
standard 6 French afterloading catheters.
• The legs of the applicator sort through the
nostrils and are fixed with a silicone bridge,
pushed against the nasal septum
101.
102.
103.
104. Nasopharynx Implant points
• Tumor tissue points
Node of Rouviere (R)
Nasopharynx (Na)
• Normal tissue points
Spinal cord, soft palate, base of skull, pituitary
gland, optic chiasm, and retina
108. Endemic NPC
• known to occur in China, Hong Kong, South
Eastern Asia, Greenland
• Associated with EBV virus infection
• In India similar pathology seen in Kashmiris.
• Present a decade younger.
• Not associated with smoking or alcohol
consumption
109. • Associated with undifferentiated carcinoma ( WHO II and
III)
• Associated with more advanced disease at presentation
• Nodal stage also more advanced and more frequently
involved.
• Both chemo and radio sensitive
• Histologically more vascularized (Better Rx response)
• Greater % of cell in the growth fraction.
• Better loco regional control and survival than sporadic
variants. Several markers for predicting biological
behavior